Protocol Ledger

NCT05864105 · Phase II · COMPLETED

PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma

Interventional Phase II clinical trial protocol NCT05864105 sponsored by Biotheus in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-04-22 Enrollment: 35 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05864105
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)35 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05864105
Protocol FieldVerified Registry Value
NCT IdentifierNCT05864105
Consolidated Lead SponsorBiotheus
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment35 participants (ACTUAL)
Registered Start Date2022-04-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05864105
Hospital Research SiteLocationSite Profile
Anhui Provincial HospitalHefei, ChinaOpen Hospital Dossier ->
Fujian Cancer HospitalFuzhou, ChinaOpen Hospital Dossier ->
The First Affiliated Hospital, Sun-Yat Sen UniversityGuangzhou, ChinaOpen Hospital Dossier ->
Henan Cancer HospitalZhengzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI